A-shares closed · 港股休市 Quotes 行情 · 25 Sep 17:19 CST
26 Sep 2026 · 05:57 CST Terminal Access 终端入口 →
688428.SH上海证券交易所 · 科创板 STAR

Innocare 诺诚健华

Chemical Pharmaceuticals 化学制药
¥29.86−¥3.54 · −10.60%Delayed 行情延迟 · 24 Sep 2026 · 16:14 CST · CNY
Open 开盘
¥33.14
High 最高
¥35.00
Low 最低
¥29.80
Prev Close 昨收
¥33.40
Volume 成交量
3,031.8万股
Turnover 成交额
¥9.51亿
Mkt Cap 总市值
¥528亿
P/E 市盈率
57.5×
Recent Activity 近期动态All Filings 全部公告 →

19 significant filings since 29 May 2026: 15 on equity incentive, 2 on major holder selling and 1 on major contract or bid won, and 1 other kind. The latest, on 24 Sep 2026: 诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告.
自 29 May 2026 起有 19 份重大公告:equity incentive 15 份、major holder selling 2 份、major contract or bid won 1 份,另有 1 类。最新一份(24 Sep 2026):诺诚健华医药有限公司关于子公司与礼来公司签署研发合作及授权许可协议的公告。

Price History 价格走势

66 trading days 个交易日 · High 最高 ¥33.40 · Low 最低 ¥24.86
26.0028.0030.0032.00
Volume 成交量
3,031.8万
25 Jun17 Jul10 Aug02 Sep24 Sep

Against Its Own History 与自身历史比较

57.5×
Median 中值 54.0× · Range 区间 52.7× to 62.8× · 3 periods 期
6.88×
Median 中值 3.25× · Range 区间 2.07× to 7.55× · 16 periods 期

Period by Period 逐期

Period 报告期Close at Period End 期末收盘TTM EPS 滚动每股收益 BPS 每股净资产
30 Jun 2026 中报¥28.47¥0.5452.7×¥4.346.56×
31 Mar 2026 一季报¥27.02¥0.4362.8×¥4.166.49×
31 Dec 2025 年报¥20.52¥0.3854.0×¥4.384.69×
30 Sep 2025 三季报¥28.52−¥0.14—¥3.787.55×
30 Jun 2025 中报¥24.43−¥0.12—¥3.806.42×
31 Mar 2025 一季报¥18.71−¥0.17—¥3.834.89×
31 Dec 2024 年报¥12.28−¥0.26—¥3.823.22×
30 Sep 2024 三季报¥12.94−¥0.22—¥3.863.35×
30 Jun 2024 中报¥8.11−¥0.28—¥3.922.07×
31 Mar 2024 一季报¥9.52−¥0.44—¥3.992.39×
31 Dec 2023 年报¥11.50−¥0.37—¥4.052.84×
30 Sep 2023 三季报¥10.32−¥0.32—¥4.162.48×
30 Jun 2023 中报¥11.55−¥0.54—¥4.232.73×
31 Mar 2023 一季报¥11.84−¥0.53—¥4.262.78×
31 Dec 2022 年报¥14.11−¥0.60—¥4.313.28×
30 Sep 2022 三季报¥9.11−¥0.70—¥4.382.08×

Consensus Forward EPS 机构预测每股收益

Fiscal Year 年度EPS Median 中值Range 区间Brokers 机构数Forward P/E 预测市盈率
2026¥0.14¥0.12 to ¥0.274213.3×
2027¥0.11¥0.10 to ¥0.124271.5×
2028¥0.24¥0.22 to ¥0.524121.9×
Not Computed 未计算
  • Dividend Yield 股息率
  • Free Cash Flow 自由现金流
  • EV/EBITDA